Ever wonder how scientists actually measure the "importance" of a research journal? It's not vibes. That's why it's not gut feeling. There's a number attached to nearly every journal you can think of, and for proteomics researchers, the Molecular and Cellular Proteomics impact factor* is one of the most-watched metrics in the field.
But here's the thing — most people Googling this aren't really after a single number. They want to know what the impact factor means, why it matters (or doesn't), and how MCP (as it's usually called) stacks up against other journals. So let's actually get into it.
What Is the Molecular and Cellular Proteomics* Impact Factor?
The impact factor is a number, calculated annually by Clarivate, that reflects how often articles from a journal get cited in other scholarly papers during a specific window. The standard formula: take the total citations in year X to articles published in years X-1 and X-2, then divide by the total number of "citable items" published in those same two years.
So if MCP has an impact factor of, say, 7, that means articles it published two and three years ago got cited, on average, seven times in the most recent year. Which means that's a lot of citations. For context, the median journal in biochemistry has an impact factor hovering around 3 to 4.
MCP has historically sat in a comfortable upper tier. Recent figures have put its impact factor in the mid-6s to low-7s range, depending on the year. Some years it dips, some years it climbs — that's normal. Impact factors wobble.
What's the Journal Itself?
Before we go further, worth saying: Molecular and Cellular Proteomics* isn't some random publication. That's why it's the flagship journal of the American Society for Biochemistry and Molecular Biology (ASBMB). It publishes peer-reviewed work on proteomics — the large-scale study of proteins, their structures, functions, and interactions.
The journal is open access, which is a meaningful detail. Worth adding: authors pay an article processing charge, and readers get free access. This has implications for the impact factor, which we'll get to.
Why the Impact Factor Matters (And Why It Sometimes Doesn't)
Let's be honest about something: the impact factor is a blunt instrument. In practice, it tells you roughly how influential a journal is in aggregate, but it says nothing about your* paper specifically. But a single article in a low-impact-factor journal can change a field. A single article in a high-impact-factor journal can be ignored forever.
That said, the impact factor still matters in practice. Here's why:
- Hiring and tenure committees use it as a quick proxy for "quality." It's imperfect, but it's easy.
- Grant reviewers sometimes look at where you publish, not just what you publish.
- Authors chase high-impact journals for visibility, and MCP sits near the top of the proteomics pile.
- Institutional rankings in some countries still weight publication metrics heavily.
So even with all the criticism — and there's a lot of criticism — the impact factor keeps showing up on CVs, in lab discussions, and on department websites.
How the Impact Factor Is Actually Calculated
Here's the step-by-step, because most people only sort-of know how it works:
- Take a two-year window — say, 2022 and 2023.2. Count every "citable item" MCP published in those years. These are usually research articles and reviews, not editorials or corrections.
- Now look at all of 2024. Count every time a 2024 paper cited something MCP published in 2022 or 2023.4. Divide the citation count by the article count.
That's it. The number you get is the journal impact factor for 2024 (using the 2024 release).
A couple of sneaky things affect this number. Because of that, review articles tend to get cited more than research articles, so journals that publish lots of reviews can inflate their IF. MCP publishes a mix, and the editorial team is aware of how this plays into the metric — but they don't, to their credit, game it heavily.
How MCP Stacks Up Against Other Proteomics Journals
Proteomics is a relatively small field, so there aren't dozens of top-tier journals competing for the same papers. The main ones to know:
- Journal of Proteome Research — published by ACS, has an impact factor in the mid-3s to low-4s.
- Proteomics — a Wiley title, historically in a similar range, though it's gone through some changes over the years.
- Nature Methods and Molecular Systems Biology — not proteomics-specific, but they publish high-impact papers on proteomics methods when the work is broadly significant. Their impact factors are much higher (often 10+).
MCP sits in a sweet spot. It's not as broad as a Nature-family journal, but it has more prestige and reach than its direct proteomics competitors. For a proteomics researcher, publishing in MCP is a real signal that your work is rigorous and relevant.
A Note on Open Access and the IF
Because MCP is fully open access, there's been some debate about whether this boosts citations (and therefore the impact factor). That's why the answer is: probably, yes. But this isn't a flaw — it's a feature. The journal's editorial standards haven't been compromised by going open access. Even so, open access papers tend to get cited more often because anyone can read them. If anything, the visibility has helped it compete with subscription-based journals.
Common Misconceptions About the MCP Impact Factor
Here's where I want to push back on a few things I see repeated online.
"The impact factor is the best measure of journal quality." No, it isn't. It's one measure, and a flawed one. It rewards citation count*, not citation quality*. A paper can be cited critically — meaning other researchers are pushing back on it — and that still counts.
Want to learn more? We recommend acs organic chemistry exam 2016 pdf and scientists have discovered a mystery compound in us drinking water. for further reading.
"A high impact factor means a fast review process." Often the opposite. Prestigious journals tend to have rigorous, sometimes slow, peer review. MCP is no exception.
"Impact factors don't change much year to year." They actually do. Small changes in citation patterns can shift a journal's IF by 10–20% in a single year. Don't read too much into small movements.
"If a paper is in MCP, it must be good." Quality is high on average, sure. But every journal publishes a range of papers. Some MCP papers are landmark contributions; others are solid but unremarkable. Don't worship the journal — read the paper.
What Actually Moves the Needle for Authors
If you're a researcher considering submitting to MCP, the impact factor is probably not the most important factor. Here's what I'd actually pay attention to:
- Scope fit. Does your paper belong in MCP? The journal covers protein chemistry, proteomics methods, bioinformatics applied to proteomics, and clinically-relevant proteomics work. If your paper is a pure clinical study with no methodological proteomics angle, it might be a better fit elsewhere.
- Audience. Who do you want to read this? MCP's readership is heavily proteomics-focused. If your work has broader appeal, consider Molecular Cell* or similar.
- Open access benefits. If you want maximum reach, MCP delivers.
- Cost. Article processing charges for MCP are significant. ASBMB members get a discount, and there are some waivers available for authors from low-income countries.
Practical Tips for Anyone Tracking This Metric
If you're using the impact factor to evaluate journals — for a literature review, a CV, a job search — here are some honest suggestions.
First, look at the 5-year impact factor, not just the 2-year one. The 5-year IF smooths out the year-to-year noise and gives a more stable picture of a journal's influence. Clarivate publishes both.
Second, check multiple sources. Worth adding: the Clarivate Journal Citation Reports (JCR) is the official source, but Elsevier's Scopus has its own metric called CiteScore. They don't always agree, and that's actually useful — it tells you the picture is more complicated than one number suggests.
Third, look at the journal's own website and editorial statements. MCP has been transparent about its editorial philosophy and the role of metrics. Reading that gives you context you won't get from a number alone.
Finally, consider Altmetric and download data. These tell you how much attention a paper
or journal is getting beyond formal citations — social media mentions, news coverage, policy document citations. For proteomics, which often has immediate practical applications in biomarker discovery and drug development, these alternative metrics can be especially informative.
A Reality Check for the Impact Factor Obsession
The scientific community has been reckoning with the misuse of impact factors for years. In real terms, the San Francisco Declaration on Research Assessment* (DORA), signed by thousands of organizations and journals, explicitly recommends that funders and institutions not use journal impact factors as a proxy for the quality of individual research or scientists. MCP has been a signatory to related initiatives and has publicly discussed these issues.
Yet the impact factor persists as a shorthand. But grant reviewers may (consciously or not) weight publications in higher-IF journals more heavily. Hiring committees glance at where candidates publish. Early-career researchers feel pressure to chase the metric.
The honest truth is this: the impact factor of MCP tells you something about the journal's standing in the proteomics community, but it tells you very little about any specific paper, and almost nothing about you as a scientist. Your weakest paper could squeak into a high-IF journal. Your best paper could land in a lower-IF journal because of bad luck in timing or reviewer assignment. The signal-to-noise ratio of using journal IF to evaluate science is poor.
The Bigger Picture for Proteomics Publishing
Looking at MCP's impact factor trajectory is really a window into the state of proteomics publishing more broadly. So mass spectrometry has become more sensitive, more accessible, and more quantitative. Worth adding: the field has matured dramatically since the journal's founding. New technologies — single-cell proteomics, spatial proteomics, top-down proteomics, multi-omics integration — are pushing the field forward and creating new publication venues.
Specialty journals have proliferated. MCP now shares the landscape with journals like Journal of Proteome Research*, Molecular & Cellular Proteomics* (itself), Proteomics*, Nature Methods* (for methods papers), and numerous clinical proteomics titles. The competition for the best proteomics papers is fierce.
In this environment, MCP's strong impact factor reflects both its historical strength and its continued ability to attract top-tier work. Even so, the journal's open access model, its association with the respected ASBMB, and its rigorous editorial standards all contribute. But sustaining that position requires constant effort — adapting to new technologies, maintaining fast but fair peer review, and serving a community that has many options.
Wrapping Up: The Number in Context
The 2024 impact factor of around 7 is a data point, not a verdict. It places Molecular & Cellular Proteomics* solidly in the upper tier of specialist journals, reflecting its importance to the proteomics community. But the impact factor is one measure among many, and arguably not even the best one for evaluating the kind of work MCP publishes.
If you're an author, focus on fit, audience, and the quality of the science rather than the prestige number. Day to day, if you're a reader or evaluator, consider multiple metrics, read the actual papers, and remember that good science appears in many venues. If you're curious about the field, the impact factor tells you proteomics publishing is healthy and competitive, with MCP remaining a central player.
The metric will continue to wobble year to year, as it always does. What won't change is the underlying value of rigorous, well-communicated science — wherever it appears.
